

Celldex Therapeutics, Inc.  
Form SC 13D/A  
December 15, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**(Rule 13d-101)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO**  
**13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)**

**(Amendment No. 5)<sup>1</sup>**

**Celldex Therapeutics, Inc.**

**(Name of Issuer)**

**Common Stock par value \$0.001 per share**

**(Title Class of Securities)**

**15117B103**

**(CUSIP Number)**

**Bristol-Myers Squibb Company**

**345 Park Avenue**

**New York, New York 10154**

**(212) 546-4000**

**Attn: General Counsel**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**December 14, 2009**

**(Date of Event which Requires Filing of this Statement)**

## Edgar Filing: Celldex Therapeutics, Inc. - Form SC 13D/A

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

<sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see the Notes*)

1 NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION OF ABOVE PERSON

Medarex, Inc.

IRS Identification Number 22-2822175

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  (b)

3 SEC USE ONLY

4 SOURCE OF FUNDS\*

AF, OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 7 SOLE VOTING POWER

SHARES

BENEFICIALLY 0

OWNED BY 8 SHARED VOTING POWER

EACH

REPORTING 1,892,819  
9 SOLE DISPOSITIVE POWER

PERSON

WITH

0  
10 SHARED DISPOSITIVE POWER

1,892,819  
**11** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,892,819  
**12** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

**13** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.99%  
**14** TYPE OF REPORTING PERSON

CO

\* SEE INSTRUCTION BEFORE FILLING OUT

15 NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION OF ABOVE PERSON

Bristol-Myers Squibb Company

IRS Identification Number 22-0790350

16 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a)  (b)

17 SEC USE ONLY

18 SOURCE OF FUNDS\*

AF, OO

19 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

20 CITIZENSHIP OR PLACE OF ORGANIZATION

X

Delaware

NUMBER OF 21 SOLE VOTING POWER

SHARES

BENEFICIALLY 0

OWNED BY 22 SHARED VOTING POWER

EACH

REPORTING 1,892,819  
23 SOLE DISPOSITIVE POWER

PERSON

WITH

0  
24 SHARED DISPOSITIVE POWER

Edgar Filing: Celldex Therapeutics, Inc. - Form SC 13D/A

1,892,819  
25 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,892,819  
26 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

27 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.99%  
28 TYPE OF REPORTING PERSON

CO

**CUSIP No. 15117B103****13D****Page 4 of 5**

This Amendment No. 5 (the Schedule 13D/A ) amends the Statement on Schedule 13D/A (the Schedule 13D ) filed with the Securities and Exchange Commission (the SEC ) on December 9, 2009 by Medarex, Inc. ( Medarex ) and Bristol-Myers Squibb Company ( Bristol-Myers ) and together with Medarex, the Reporting Persons ). The number of securities beneficially owned by the Reporting Persons has materially decreased. The Schedule 13D is amended as follows and, except as otherwise provided herein, all items of the Schedule 13D remain unchanged.

**Item 5. Interest in Securities of the Issuer**

The Reporting Persons beneficially own 1,892,819 shares of the Common Stock (5.99% of the Celldex s issued and outstanding shares of Common Stock, based upon information set forth in the Celldex s Form 10-Q for the quarter ended September 30, 2009, indicating that 31,602,188 shares of Common Stock were issued and outstanding on September 30, 2009). The Reporting Persons share voting and investment power with regard to all 1,892,819 shares of Common Stock that they beneficially own. To the knowledge of the Reporting Persons, none of the officers and directors of the Reporting Persons is the beneficial owner of any shares of the Common Stock of Celldex.

The following dispositions of Common Stock were effected on the following dates and at the following prices since the most recent filing of Schedule 13D/A on December 9, 2009:

<b>Date</b>	<b>No. of Shares</b>	<b>Price Per Share*</b>
December 10, 2009	49,500	\$ 4.53
December 11, 2009	106,235	\$ 4.44
December 14, 2009	305,000	\$ 4.76
December 15, 2009	121,393	\$ 4.44

**Item 7. Material to be Filed as Exhibits**

Not Applicable.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**MEDAREX, INC.**

Date: December 15, 2009

By: /s/ SONIA VORA  
Name: Sonia Vora  
Title: Secretary

**BRISTOL-MYERS SQUIBB COMPANY**

Date: December 15, 2009

By: /s/ SANDRA LEUNG  
Name: Sandra Leung  
Title: Senior Vice President and General Counsel